Anchiano Therapeutics Chairman Stephen Hoffman Steps Down from Board
October 24, 2019 16:05 ET
|
Anchiano Therapeutics
CAMBRIDGE, Mass., Oct. 24, 2019 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (“Anchiano” or the “Company”), a pivotal-stage biopharmaceutical company focused on the discovery and...
Anchiano Therapeutics Enters into An Exclusive Option To License Agreement for Novel Pan-RAS Inhibitor and PDE10/β-catenin Inhibitor Programs
September 23, 2019 17:03 ET
|
Anchiano Therapeutics
Anchiano will make an upfront payment in exchange for the option to in-license at any time through obtaining an Investigational New Drug (IND) designation Company also provides update on accrual to...
Anchiano Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference
September 20, 2019 08:30 ET
|
Anchiano Therapeutics
CAMBRIDGE, Mass., Sept. 20, 2019 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (“Anchiano”), a pivotal-stage biopharmaceutical company focused on the discovery and development of...
Anchiano Therapeutics to Present at the Baird 2019 Global Healthcare Conference
September 03, 2019 08:00 ET
|
Anchiano Therapeutics
CAMBRIDGE, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (“Anchiano”), a pivotal-stage biopharmaceutical company focused on the discovery and development of...
Anchiano Therapeutics Reports Second Quarter 2019 Financial Results
August 05, 2019 17:15 ET
|
Anchiano Therapeutics
CAMBRIDGE, Mass., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (“Anchiano”), a pivotal-stage biopharmaceutical company focused on the discovery and development of...
Anchiano Therapeutics Delists Ordinary Shares from the Tel Aviv Stock Exchange
June 18, 2019 08:30 ET
|
Anchiano Therapeutics
CAMBRIDGE, Mass., June 18, 2019 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (“Anchiano”), a pivotal-stage biopharmaceutical company focused on the discovery and development of...
Anchiano Therapeutics Announces Appointment of Salar Roshan as Head of Business Development
May 29, 2019 08:30 ET
|
Anchiano Therapeutics
CAMBRIDGE, Mass., May 29, 2019 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq and TASE: ANCN) (“Anchiano”), a pivotal-stage biopharmaceutical company focused on the discovery and development...
Anchiano Therapeutics Reports First Quarter 2019 Financial Results
May 22, 2019 09:00 ET
|
Anchiano Therapeutics
– Closed $30.5 million U.S. Initial Public Offering in February 2019 – CAMBRIDGE, Mass., May 22, 2019 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq and TASE: ANCN) (“Anchiano”), a...
Anchiano Therapeutics to Present at the Oppenheimer 29th Annual Healthcare Conference
March 14, 2019 17:42 ET
|
Anchiano Therapeutics
CAMBRIDGE, Mass., March 14, 2019 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq and TASE: ANCN) (“Anchiano”), a pivotal-stage biopharmaceutical company focused on the discovery and...
Anchiano Therapeutics Initiates Process to Voluntarily Delist its Ordinary Shares from the Tel Aviv Stock Exchange
March 14, 2019 08:16 ET
|
Anchiano Therapeutics
CAMBRIDGE, Mass., March 14, 2019 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq and TASE: ANCN) (“Anchiano”) today announced an update with respect to its intention to voluntarily delist its...